Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843206 | 1.00 | ACE (0.53) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL7339038 | 1.00 | ACE (0.53) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL4848858 | 1.00 | ACE (0.53) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL4842577 | 1.00 | ACE (0.53) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL19042 | 0.97 | ACE (0.53) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL16276265 | 0.91 | HTR2C (0.48) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL7345709 | 0.90 | SMN1; SMN2 (0.52) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL9877388 | 0.89 | FKBP1A (0.49) | ACEMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL9878033 | 0.89 | FKBP1A (0.49) | ACEMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL26397763 | 0.88 | HTR2C (0.52) | MEN1KMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439036-B2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-21 | — | — | US | disclosed |
| EP-1536017-B1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL CO (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1536017-A2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | Sumitomo Chemical Company, Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | IDO1, IDO2, APEH | ACE 1148/4885MEN1 1912/4885KMT2A 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.